用于急性淋巴细胞白血病治疗的纳米药物递送系统
Nanodrug Delivery Systems for Acute Lymphoblastic Leukemia Therapy.
作者信息
Yang Aiyun, Lu Yuanfang, Zhang Zuo, Wang Jianhua
机构信息
Translational Medicine Laboratory, Beijing Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Beijing 100020, China.
Beijing Key Laboratory of Environmental & Viral Oncology, College of Life Science & Bioengineering, Beijing University of Technology, Beijing 100124, China.
出版信息
Pharmaceuticals (Basel). 2025 Apr 27;18(5):639. doi: 10.3390/ph18050639.
Acute lymphoblastic leukemia (ALL) is a malignant tumor caused by abnormal proliferation of B-line or T-line lymphocytes in the bone marrow. Traditional treatments have limitations. Because of their unique advantages, nanodrug delivery systems (NDDSs) show great potential in the treatment of ALL. In this paper, the pathological features of ALL, the limitations of current therapeutic methods, and the definition and composition of NDDSs were reviewed. Research strategies for the use of NDDSs in the treatment of ALL were discussed. In addition, challenges and future development directions of NDDSs in the treatment of ALL were also discussed, aiming to provide reference for the application of NDDSs in the diagnosis and treatment of ALL.
急性淋巴细胞白血病（ALL）是一种由骨髓中B淋巴细胞或T淋巴细胞异常增殖引起的恶性肿瘤。传统治疗方法存在局限性。由于具有独特优势，纳米药物递送系统（NDDSs）在ALL治疗中显示出巨大潜力。本文综述了ALL的病理特征、当前治疗方法的局限性以及NDDSs的定义和组成。讨论了使用NDDSs治疗ALL的研究策略。此外，还讨论了NDDSs在ALL治疗中的挑战和未来发展方向，旨在为NDDSs在ALL诊断和治疗中的应用提供参考。
Zotero 插件